News

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Additional Cohort 1 Data to be Reported in 1H25 Building on Promising Initial Data Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today provided an update on its clinical development programs and outlined its strategic priorities for 2025.

01/13/2025

Tenaya Therapeutics price target lowered to $6 from $8 at Leerink

Leerink lowered the firm's price target on Tenaya Therapeutics to $6 from $8 and keeps an Outperform rating on the shares after the company announced initial Phase 1b/2 MyPEAK-1 data for TN-201 in MYBPC3-associated hypertrophic cardiomyopathy following program updates in October. The firm notes that while evidence of expression was present, clinical benefit is yet to be determined. Updated Cohort 1 data are expected in the first half of 2025, while initial Cohort 2 and MyClimb natural history data are expected in 2025.

12/17/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Tenaya Therapeutics, Inc. (TNYA) a buy, sell, or hold?

Tenaya Therapeutics, Inc. (TNYA) can sell. Click on Rating Page for detail.

What is Tenaya Therapeutics, Inc.'s stock price?

The price of Tenaya Therapeutics, Inc. (TNYA) is 1.21 and it was updated on 2025-01-25 02:54:57.

Is Tenaya Therapeutics, Inc. (TNYA) overvalued or undervalued?

Currently Tenaya Therapeutics, Inc. (TNYA) is in undervalued.

News

From:

To:

News
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET Mon, Dec. 16, 2024
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAK TM -1 Phase 1b/2 Trial of TN-201 Gene Therapy Wed, Nov. 06, 2024
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Thu, Oct. 17, 2024
Tenaya Therapeutics to Participate in Upcoming Investment Conferences SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's chief Executive Officer, will participate in several upcoming investment conferences. Details are as follows: Tue, Sep. 03, 2024
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street Penny stocks represent an interesting investment opportunity. Tue, Jul. 30, 2024

SEC Filings

SEC Filings
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 12/17/2024
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 11/18/2024
Tenaya Therapeutics, Inc. (TNYA) - SC 13G/A SEC Filings 11/14/2024
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 11/06/2024
Tenaya Therapeutics, Inc. (TNYA) - 10-Q - Quarterly Report SEC Filings 11/06/2024
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 10/21/2024
Tenaya Therapeutics, Inc. (TNYA) - S-8 SEC Filings 09/17/2024
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 09/16/2024
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 08/19/2024
Tenaya Therapeutics, Inc. (TNYA) - 3 SEC Filings 08/19/2024
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 08/16/2024
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 08/08/2024
Tenaya Therapeutics, Inc. (TNYA) - 10-Q - Quarterly Report SEC Filings 08/08/2024
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 07/25/2024
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 06/27/2024
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 05/31/2024
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 05/14/2024
Tenaya Therapeutics, Inc. (TNYA) - 10-Q - Quarterly Report SEC Filings 05/14/2024
Tenaya Therapeutics, Inc. (TNYA) - DEFA14A SEC Filings 04/17/2024
Tenaya Therapeutics, Inc. (TNYA) - DEF 14A SEC Filings 04/17/2024
Tenaya Therapeutics, Inc. (TNYA) - ARS SEC Filings 04/17/2024
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 03/18/2024
Tenaya Therapeutics, Inc. (TNYA) - 10-K - Current report SEC Filings 03/18/2024
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 03/06/2024
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 02/27/2024
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 02/21/2024
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 02/16/2024
Tenaya Therapeutics, Inc. (TNYA) - SC 13G/A SEC Filings 02/14/2024
Tenaya Therapeutics, Inc. (TNYA) - SC 13D/A SEC Filings 02/14/2024
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 02/14/2024
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 02/08/2024
Tenaya Therapeutics, Inc. (TNYA) - 424B5 SEC Filings 02/08/2024
Tenaya Therapeutics, Inc. (TNYA) - SC 13G SEC Filings 01/31/2024
Tenaya Therapeutics, Inc. (TNYA) - S-8 SEC Filings 01/31/2024
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 11/08/2023
Tenaya Therapeutics, Inc. (TNYA) - 10-Q - Quarterly Report SEC Filings 11/08/2023
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 08/29/2023
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 08/18/2023
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 08/09/2023
Tenaya Therapeutics, Inc. (TNYA) - 10-Q - Quarterly Report SEC Filings 08/09/2023
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 06/12/2023
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 06/12/2023
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 05/10/2023
Tenaya Therapeutics, Inc. (TNYA) - 10-Q - Quarterly Report SEC Filings 05/10/2023
Tenaya Therapeutics, Inc. (TNYA) - DEFA14A SEC Filings 04/27/2023
Tenaya Therapeutics, Inc. (TNYA) - DEF 14A SEC Filings 04/27/2023
Tenaya Therapeutics, Inc. (TNYA) - PRE 14A SEC Filings 04/17/2023
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 03/21/2023
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 03/14/2023
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 03/13/2023
Tenaya Therapeutics, Inc. (TNYA) - S-8 SEC Filings 03/08/2023
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 03/08/2023
Tenaya Therapeutics, Inc. (TNYA) - 10-K - Current report SEC Filings 03/08/2023
Tenaya Therapeutics, Inc. (TNYA) - SC 13D/A SEC Filings 02/21/2023
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 02/17/2023
Tenaya Therapeutics, Inc. (TNYA) - SC 13G/A SEC Filings 02/14/2023
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 02/10/2023
Tenaya Therapeutics, Inc. (TNYA) - SC 13G/A SEC Filings 02/09/2023
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 01/23/2023
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 01/19/2023
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 12/09/2022
Tenaya Therapeutics, Inc. (TNYA) - SC 13D/A SEC Filings 12/07/2022
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 12/07/2022
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 12/07/2022
Tenaya Therapeutics, Inc. (TNYA) - 3 SEC Filings 12/07/2022
Tenaya Therapeutics, Inc. (TNYA) - SC 13D SEC Filings 12/01/2022
Tenaya Therapeutics, Inc. (TNYA) - SC 13D/A SEC Filings 11/28/2022
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 11/25/2022
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 11/23/2022
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 11/17/2022
Tenaya Therapeutics, Inc. (TNYA) - 424B5 SEC Filings 11/17/2022
Tenaya Therapeutics, Inc. (TNYA) - 424B5 SEC Filings 11/16/2022
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 11/10/2022
Tenaya Therapeutics, Inc. (TNYA) - 10-Q - Quarterly Report SEC Filings 11/10/2022
Tenaya Therapeutics, Inc. (TNYA) - SC 13G/A SEC Filings 10/11/2022
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 09/09/2022
Tenaya Therapeutics, Inc. (TNYA) - EFFECT SEC Filings 08/18/2022
Tenaya Therapeutics, Inc. (TNYA) - EFFECT SEC Filings 08/18/2022
Tenaya Therapeutics, Inc. (TNYA) - 424B5 SEC Filings 08/17/2022
Tenaya Therapeutics, Inc. (TNYA) - CORRESP SEC Filings 08/15/2022
Tenaya Therapeutics, Inc. (TNYA) - UPLOAD SEC Filings 08/12/2022
Tenaya Therapeutics, Inc. (TNYA) - S-3 SEC Filings 08/10/2022
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 08/10/2022
Tenaya Therapeutics, Inc. (TNYA) - 10-Q - Quarterly Report SEC Filings 08/10/2022
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 06/13/2022
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 06/10/2022
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 05/11/2022
Tenaya Therapeutics, Inc. (TNYA) - 10-Q - Quarterly Report SEC Filings 05/11/2022
Tenaya Therapeutics, Inc. (TNYA) - DEFA14A SEC Filings 04/28/2022
Tenaya Therapeutics, Inc. (TNYA) - DEF 14A SEC Filings 04/28/2022
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 04/28/2022
Tenaya Therapeutics, Inc. (TNYA) - S-8 SEC Filings 03/23/2022
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 03/23/2022
Tenaya Therapeutics, Inc. (TNYA) - 10-K - Current report SEC Filings 03/23/2022
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 02/17/2022
Tenaya Therapeutics, Inc. (TNYA) - SC 13G SEC Filings 02/14/2022
Tenaya Therapeutics, Inc. (TNYA) - SC 13G SEC Filings 02/11/2022
Tenaya Therapeutics, Inc. (TNYA) - SC 13G/A SEC Filings 02/09/2022
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 12/23/2021
Tenaya Therapeutics, Inc. (TNYA) - 3 SEC Filings 12/23/2021
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 12/22/2021
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 11/22/2021
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 11/22/2021
Tenaya Therapeutics, Inc. (TNYA) - 3 SEC Filings 11/22/2021
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 11/10/2021
Tenaya Therapeutics, Inc. (TNYA) - 10-Q - Quarterly Report SEC Filings 11/10/2021
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 09/08/2021
Tenaya Therapeutics, Inc. (TNYA) - 10-Q - Quarterly Report SEC Filings 09/08/2021
Tenaya Therapeutics, Inc. (TNYA) - SC 13G SEC Filings 08/10/2021
Tenaya Therapeutics, Inc. (TNYA) - SC 13G SEC Filings 08/09/2021
Tenaya Therapeutics, Inc. (TNYA) - SC 13D SEC Filings 08/09/2021
Tenaya Therapeutics, Inc. (TNYA) - 4 SEC Filings 08/04/2021
Tenaya Therapeutics, Inc. (TNYA) - 8-K - Current report SEC Filings 08/03/2021
Tenaya Therapeutics, Inc. (TNYA) - SEC STAFF LETTER SEC Filings 08/02/2021
Tenaya Therapeutics, Inc. (TNYA) - EFFECT SEC Filings 07/30/2021
Tenaya Therapeutics, Inc. (TNYA) - S-8 SEC Filings 07/30/2021
Tenaya Therapeutics, Inc. (TNYA) - 424B4 SEC Filings 07/30/2021
Tenaya Therapeutics, Inc. (TNYA) - EFFECT SEC Filings 07/29/2021
Tenaya Therapeutics, Inc. (TNYA) - S-1MEF SEC Filings 07/29/2021
Tenaya Therapeutics, Inc. (TNYA) - 3 SEC Filings 07/29/2021
Tenaya Therapeutics, Inc. (TNYA) - CORRESP SEC Filings 07/27/2021
Tenaya Therapeutics, Inc. (TNYA) - CERT SEC Filings 07/27/2021
Tenaya Therapeutics, Inc. (TNYA) - S-1/A SEC Filings 07/26/2021
Tenaya Therapeutics, Inc. (TNYA) - CORRESP SEC Filings 07/26/2021
Tenaya Therapeutics, Inc. (TNYA) - 8-A12B SEC Filings 07/23/2021
Tenaya Therapeutics, Inc. (TNYA) - UPLOAD SEC Filings 07/15/2021
Tenaya Therapeutics, Inc. (TNYA) - S-1 SEC Filings 07/09/2021
Tenaya Therapeutics, Inc. (TNYA) - CORRESP SEC Filings 07/09/2021
Tenaya Therapeutics, Inc. (TNYA) - UPLOAD SEC Filings 06/24/2021
Tenaya Therapeutics, Inc. (TNYA) - DRS/A SEC Filings 06/16/2021
Tenaya Therapeutics, Inc. (TNYA) - DRSLTR SEC Filings 06/15/2021
Tenaya Therapeutics, Inc. (TNYA) - SEC STAFF LETTER SEC Filings 06/10/2021
Tenaya Therapeutics, Inc. (TNYA) - UPLOAD SEC Filings 06/03/2021
Tenaya Therapeutics, Inc. (TNYA) - DRS SEC Filings 05/07/2021

Press Releases

StockPrice Release
Tenaya therapeutics announces 2025 strategic priorities and anticipated milestones 01/13/2025
Tenaya therapeutics to announce initial data from mypeak-1 phase 1b/2 clinical trial of tn-201 gene therapy for mybpc3-associated hypertrophic cardiomyopathy on tuesday, december 17, 2024 12/16/2024
Tenaya therapeutics reports third quarter 2024 financial results and provides business update 11/06/2024
Tenaya therapeutics announces updates on tn-201 gene therapy program for mybpc3-associated hcm 10/17/2024
Tenaya therapeutics to participate in upcoming investment conferences 09/03/2024
Tenaya therapeutics announces research leadership updates 06/27/2024
Tenaya therapeutics to participate at the td cowen genetic medicines & rna summit 06/18/2024
Tenaya therapeutics reports first quarter 2024 financial results and provides business update 05/14/2024
Tenaya therapeutics to highlight growing capabilities in capsid engineering, gene editing and manufacturing at the american society of gene and cell therapy 27th annual meeting 05/02/2024
Tenaya therapeutics reports fourth quarter and full year 2023 financial results and provides business update 03/18/2024
Tenaya therapeutics announces publication of tn-401 gene therapy preclinical data in nature communications medicine 03/18/2024
Tenaya therapeutics to participate in upcoming march investor conferences 02/27/2024
Tenaya therapeutics announces publication of preclinical hdac6 inhibitor data for heart failure with preserved ejection fraction in nature communications 02/26/2024
Tenaya therapeutics announces pricing of underwritten offering 02/08/2024
Tenaya therapeutics to participate at the 42nd annual j.p. morgan healthcare conference 01/03/2024
Tenaya therapeutics to participate at the 35th annual piper sandler healthcare conference 11/21/2023
Tenaya therapeutics announces fda clearance to begin clinical testing of tn-401 gene therapy for the treatment of pkp2-associated arrhythmogenic right ventricular cardiomyopathy 10/26/2023
Tenaya therapeutics presents encouraging new clinical and preclinical data from hdac6 inhibitor program tn-301 for the potential treatment of heart failure with preserved ejection fraction at the 2023 hfsa annual scientific meeting 10/09/2023
Tenaya therapeutics publishes preclinical data in circulation highlighting the clinical potential of cellular reprogramming for cardiac regeneration 10/02/2023
Tenaya therapeutics to present data for tn-301 and tn-201 at upcoming medical conferences 09/21/2023
Tenaya therapeutics to participate at the 21st annual morgan stanley global healthcare conference 08/31/2023
Tenaya therapeutics reports second quarter 2023 financial results and provides business update 08/09/2023
Tenaya therapeutics reports first quarter 2023 financial results and provides business update 05/10/2023
Tenaya therapeutics receives fda fast track designation for tn-201 05/02/2023
Oxford biomedica appoints leone patterson as non-executive director 04/26/2023
Tenaya therapeutics to participate at chardan's 7th annual genetic medicines and cell therapy manufacturing summit 04/21/2023
Tenaya therapeutics to participate in upcoming investor conferences 02/07/2023
Tenaya therapeutics appoints amy burroughs to board of directors 12/07/2022
Tenaya therapeutics receives orphan drug designation from the u.s. food and drug administration for its gene therapy for genetic arrhythmogenic right ventricular cardiomyopathy 11/28/2022
Tenaya therapeutics to participate in upcoming piper sandler 34th annual healthcare conference 11/23/2022
Tenaya therapeutics announces pricing of public offering 11/17/2022
Tenaya therapeutics to present preclinical data on its novel engineered aav capsids for cardiac gene delivery at the esgct 29th annual congress 10/04/2022
Tenaya therapeutics to participate in upcoming october investor and industry conferences 09/29/2022
Tenaya therapeutics publishes preclinical data in science translational medicine detailing discovery of hdac6 inhibitor for treatment of heart failure 07/06/2022
Tenaya therapeutics launches operations of new genetic medicines manufacturing center to support the development of potentially first-in-class cardiovascular therapeutics 06/16/2022
Tenaya therapeutics to present preclinical data on tn-301 hdac6 inhibitor at european society of cardiology heart failure 2022 conference 05/20/2022
Tenaya therapeutics reports first quarter 2022 financial results and provides business update 05/11/2022
Tenaya therapeutics to present preclinical data on gene therapy programs and platform capabilities at the american society of gene and cell therapy 25th annual meeting 05/03/2022
Tenaya therapeutics to present preclinical data on tn-401 pkp2 gene therapy program at heart rhythm 2022 04/28/2022
Tenaya therapeutics to participate in upcoming investor conferences 03/24/2022
Tenaya therapeutics reports fourth quarter and year-end 2021 financial results and provides business updates 03/23/2022
Tenaya therapeutics to participate in upcoming investor conferences 01/31/2022
Tenaya therapeutics provides 2022 business updates 01/10/2022
Tenaya therapeutics appoints karah parschauer, j.d., to its board of directors and joanna auch as senior vice president of people and culture 12/22/2021
Tenaya therapeutics announces the addition of dr. june lee to its board of directors 11/22/2021
Tenaya therapeutics to participate in upcoming piper sandler 33rd annual virtual healthcare conference 11/19/2021
Tenaya therapeutics reports third quarter 2021 financial results and provides business updates 11/10/2021
Tenaya therapeutics to present preclinical data on its gene therapy programs at the esgct 28th annual congress 10/12/2021
Tenaya therapeutics to participate in upcoming investor and industry conferences 09/30/2021
Tenaya therapeutics reports second quarter 2021 financial results and provides business updates 09/08/2021
Tenaya therapeutics to present at morgan stanley 19th annual global healthcare conference 08/31/2021
Tenaya therapeutics announces closing of upsized initial public offering and exercise in full of the underwriters’ option to purchase additional shares 08/03/2021
Tenaya therapeutics announces pricing of upsized initial public offering 07/29/2021

More Headlines

News
Tenaya Therapeutics Announces Research Leadership Updates Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role 06/27/2024
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the TD Cowen Genetic Medicines & RNA Summit on Friday, June 21, 2024, at 11:20 am ET. 06/18/2024
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Initial Data from Ongoing MyPEAK™ - 1 Phase 1b of TN-201 Expected in Second Half of 2024 05/14/2024
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting Abstracts Demonstrate Tenaya's Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart Medicines Abstracts Demonstrate Tenaya's Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart Medicines 05/02/2024
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-associated ARVC in Second Half 2024 $47 Million Net Proceeds from Recent Financing Extends Cash Runway into Second Half of 2025 SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. 03/18/2024
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 03/18/2024
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Details of participation are as follows: 02/27/2024
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross? After reaching an important support level, Tenaya Therapeutics, Inc. (TNYA) could be a good stock pick from a technical perspective. TNYA recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. 02/26/2024
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications Highly selective Small Molecule HDAC6 Inhibitor Effectively Reversed Heart Failure and Improved Diastolic Heart Function Alone or in Combination with SGLT2 Inhibitor in Murine Models of Disease 02/26/2024
Insider Buying: Taking a Controlling Stake in a Struggling Retailer? The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment. 02/18/2024
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 273.1% in Tenaya Therapeutics, Inc. (TNYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. 02/09/2024
Tenaya Therapeutics Announces Pricing of Underwritten Offering SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten offering of 8,888,890 shares of its common stock at an offering price of $4.50 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 2,222,271 shares of its common stock at a purchase price of $4.499 per each pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. All of the securities are to be sold by Tenaya. The deal included participation from new and existing investors including The Column Group, RA Capital Management, Venrock Healthcare Capital Partners, Octagon Capital, funds and accounts managed by BlackRock, Armistice Capital, Integral Health Asset Management, PFM Health Sciences, LP, Soleus Capital, as well as two large investment management firms. Before deducting the underwriting discounts and commissions and offering expenses, Tenaya expects to receive total gross proceeds of approximately $50 million. The offering is expected to close on or about February 12, 2024, subject to satisfaction of customary closing conditions. 02/08/2024
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why Tenaya Therapeutics, Inc. (TNYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). 01/26/2024
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, at 9:45 am PT. 01/03/2024
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the 35th Annual Piper Sandler Healthcare Conference taking place in New York, NY. 11/21/2023
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy PKP2 Mutations Are the Leading Cause of ARVC, a Dangerous Condition Linked to Sudden Cardiac Arrest in Young People Estimated to Affect 70,000 People in the US 10/26/2023
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants 10/09/2023
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publication of preclinical research in the October 3, 2023 issue of the American Heart Association's (AHA) journal, Circulation. 10/02/2023
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting 09/21/2023
Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the 21st Annual Morgan Stanley Global Healthcare Conference taking place in New York City. Details of participation are as follows: 08/31/2023
Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401 Anticipated in Second Half 2023 Second Quarter Cash and Investments of $152 Million; Runway to Fund Operations into First Half 2025 SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the second quarter ended June 30, 2023. 08/09/2023
Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 217.6% in Tenaya Therapeutics, Inc. (TNYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. 05/15/2023
3 Penny Stocks to Buy for 100% Returns Penny stocks are one of the easiest ways to make multibagger gains in the market. However, when looking at penny stocks to buy, you have to be comfortable taking the risk that comes with these speculative names. 04/23/2023
Why This Nasdaq Stock Caught Fire This Week Two premium-laden buyouts sparked a wave of bargain hunting in biotech this week. Tenaya Therapeutics, a clinical-stage gene therapy company, was one of the industry's biggest winners. 04/20/2023
Tenaya Therapeutics to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in the SVB Securities Global Biopharma Conference and Cowen's 43rd Annual Health Care Conference. Details of participation are as follows: 02/07/2023
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Buy: Here's What You Should Know Tenaya Therapeutics, Inc. (TNYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). 01/26/2023
4 Penny Stocks To Buy In January According To Insiders Penny stocks to buy according to these insiders in January. The post 4 Penny Stocks To Buy In January According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 01/20/2023
5 Penny Stocks To Buy According To Analysts, Targets Up To 992% Analysts say these are penny stocks to buy. Do you agree? 11/14/2022
Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that it will present new preclinical data on its novel AAV capsids for cardiac gene delivery at the 29th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), October 11 - 14, 2022 in Edinburgh, Scotland. 10/04/2022
Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced that it will present preclinical data at the European Society of Cardiology (ESC) Heart Failure 2022 conference. 05/20/2022
Tenaya Therapeutics to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today announced participation in two upcoming investor conferences. 03/24/2022
Why Earnings Season Could Be Great for Tenaya Therapeutics (TNYA) Tenaya Therapeutics (TNYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. 02/08/2022
Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced today that it will present new preclinical data at the ESGCT 28th Annual Congress. 10/12/2021
Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $TNYA--Tenaya Therapeutics announced today that Faraz Ali, Chief Executive Officer, will participate in upcoming investor and industry conferences. 09/30/2021
Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $TNYA--Tenaya Therapeutics reported business and program updates and second quarter 2021 financial results. 09/08/2021
Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms Tenaya Therapeutics is developing therapies for rare genetic disorders and more prevalent cardiovascular diseases. 08/06/2021

Unlock

TNYA Ratings Summary

TNYA Quant Ranking